EDELIFE - Ectodermal Dysplasia Clinical Trial. Recruiting Now!
Message from Sponsor
Background:
Pierre Fabre in currently recruiting for an open-label Phase 2 trial to investigate the efficacy and the safety of intra-amniotic administration of ER004 in male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED). Learn more about the study by visiting our provider website at https://pro.edelifeclinicaltrial.com/.
A peer-reviewed publication documenting findings to date is already available here A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement .
Pierre Fabre has partnered with the National Foundation for Ectodermal Dysplasia and Esperare to serve the needs of this rare disease community but we need your help for early referrals and recruitment. If you have an eligible patient or family to refer please contact the U.S. study investigator Dr. Grange.
U.S. trial site St. Louis, MO
Dr. Dorothy Katherine Grange
Washington University
660 South Euclid Ave
St. Louis, MO 63110
+1 314 454 6093
